Back to Awarded Treatment Trials


Awarded Trial: 06TGF-966

Grant ID

06TGF-966

Illness

Schizophrenia

Primary Drug/Intervention

Varenicline

Primary Dosage

1 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Hong

Sample Size

60

Duration of Study Period for Each Subject

9 weeks

Outcome Measurements

BPRS, Biomakers, SDS, SANS, Quality of Life, MCCB

Results

Sixty-nine (69) patients with schizophrenia, both smokers and nonsmokers, were randomized to varenicline or placebo as adjunct medication for 8 weeks. Varenicline has activity on the nicotine acetylcholine receptors. Those on varenicline had significantly reduced P-50 sensory gating and startle reactivity and improved executive function. There was also a trend toward improved symptoms but no improvement in other cognitive functions.

Publication

Hong EL, Thaker GK, McMahon RP. Effects of Moderate-Dose Treatment with Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder. Arch Gen Psychiatry Dec. 2011; 68(12):1195-1206.

Link

http://www.ncbi.nlm.nih.gov/pubmed/21810630

PI Name

L Hong

Degree

MD

Center

Maryland Psychiatric Research Centrer

Institution

University of Maryland School of Medicine

Address

PO Box 21247

City or Town

Baltimore

State or Province

MD

Zip or Postal Code

21228

Country

USA

Email Address

ehong@mprc.umaryland.edu